MediGene launches Eligard for prostate cancer in Spain

New York, Nov. 15 - MediGene AG said it launched its prostate cancer drug Eligard in Spain and plans to expand availability to 25 countries in "the next few months."

Eligard is currently available in Germany, Portugal, the Netherlands and Switzerland.

Potential annual sales in Spain were put at €100 million by the company.

The launch triggers a milestone payment from MediGene's partner, Astellas Pharma. MediGene will also receive royalties from sales of Eligard in all European countries.

MediGene is a biotechnology company located in Martinsried, Germany, and San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.